How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

801 results for

Valproic Acid Toxicity

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Prospective Study of Stereotactic Body Radiation Therapy for Thymoma Inoma: Therapeutic Effect and Toxicity Assessment

, or menopause, or attenuated by use of an approved contraceptive method (intrauterine device [IUD], birth control pills, or barrier device) during and for 2 months after trial. If male, use of an approved contraceptive method during the study and 2 months afterwards. Females with childbearing potential must have a urine negative HCG test within 7 days prior to the study enrollment. No concomitant prescriptions including cyclosporin A, valproic acid, phenobarbital, phenytoin, ketoconazole. Exclusion Criteria (...) Prospective Study of Stereotactic Body Radiation Therapy for Thymoma Inoma: Therapeutic Effect and Toxicity Assessment Prospective Study of Stereotactic Body Radiation Therapy for Thymoma Inoma: Therapeutic Effect and Toxicity Assessment - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2017 Clinical Trials

42. Retrospective review of paediatric case reports of Stevens-Johnson syndrome and toxic epidermal necrolysis with lamotrigine from an international pharmacovigilance database (PubMed)

per cent of the cases with complete information on time to onset of SJS/TEN occurred within 8 weeks of initiation of LTG therapy. The median time to onset was 15 days (IQR: 10-22 days). The proportion of SJS/TEN with LTG and valproic acid (VPA) co-reporting was significantly more than non-cutaneous ADRs (43% vs 19%, (logOR: 1.60 (99% CI: 1.33 to 1.84)).The results suggest that VPA co-medication with LTG therapy is a risk factor for SJS/TEN in the paediatric population. Although this relationship (...) Retrospective review of paediatric case reports of Stevens-Johnson syndrome and toxic epidermal necrolysis with lamotrigine from an international pharmacovigilance database This study aims to characterise paediatric reports with lamotrigine (LTG) and Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN), and to explore whether potential risk factors can be identified.This is a retrospective review of suspected adverse drug reaction (ADR) reports. Reported time from LTG start to SJS

Full Text available with Trip Pro

2017 BMJ Paediatrics Open

43. Valproic Acid With Chemoradiotherapy for Pancreatic Cancer

Center Information provided by: Soroka University Medical Center Study Details Study Description Go to Brief Summary: This is non-randomized phase 2 study to evaluate toxicity and efficacy of valproic acid (VA) with concurrent chemoradiotherapy (CCRT) containing weekly gemcitabine in patients with unresectable locally advanced pancreatic cancer (ULAPC). All patients will be planned for three-dimensional conformal radiotherapy (3-DCRT). A total dose of 54 Gy will be delivered using 2 Gy daily (...) Valproic Acid With Chemoradiotherapy for Pancreatic Cancer Valproic Acid With Chemoradiotherapy for Pancreatic Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Valproic Acid With Chemoradiotherapy

2011 Clinical Trials

44. Low Dose CdA Combined With Valproic Acid (VPA) in Previously Treated B-cell Chronic Lymphocytic Leukemia(B-CLL)

) to overcome resistance of CLL cells. Valproic acid (VPA) is an inhibitor of histone deacetylase (HDAC) used as an anticonvulsant and mood-stabilizing drug for decades. VPA mediates apoptosis in CLL cells through caspase activation. VPA shows toxicity toward CLL cells displaying alterations in the p53 pathway. The combination of VPA with fludarabine or 2-Chlorodeoxyadenosine (CdA, Cladribine) results in synergistic loss of B-CLL cell viability, and significant increase in apoptosis. The highest index (...) Low Dose CdA Combined With Valproic Acid (VPA) in Previously Treated B-cell Chronic Lymphocytic Leukemia(B-CLL) Low Dose CdA Combined With Valproic Acid (VPA) in Previously Treated B-cell Chronic Lymphocytic Leukemia(B-CLL) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2011 Clinical Trials

45. The Effect of Combination Therapy Amino Acid L-CARNITINE and Magnesium on Fatty Liver

who received TPN in the past 6 months. Patients with chronic liver disease, A1AT, Hemochromatosis, Wilson, Autoimmune, Toxic injury. Patients on anticoagulation therapy - Coumadin. Patients who use valproic acid therapy. Children, Pregnancy. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its (...) The Effect of Combination Therapy Amino Acid L-CARNITINE and Magnesium on Fatty Liver The Effect of Combination Therapy Amino Acid L-CARNITINE and Magnesium on Fatty Liver - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before

2017 Clinical Trials

46. Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration (PubMed)

compounds in addition to known environmental toxicants. The hits included the HSP90 inhibitor geldanamycin, the chemotherapeutic arsenic trioxide, the flame-retardant PBDE-99, the pesticide triadimefon and the histone deacetylase inhibitors valproic acid and trichostatin A. Transcriptome changes triggered by these substances in human neural crest cells were recorded and analysed here to answer three questions: (1) can toxicants be individually identified based on their transcript profile; (2) how can (...) Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration The in vitro test battery of the European research consortium ESNATS ('novel stem cell-based test systems') has been used to screen for potential human developmental toxicants. As part of this effort, the migration of neural crest (MINC) assay has been used to evaluate chemical effects on neural crest function. It identified some drug-like

Full Text available with Trip Pro

2015 Archives of toxicology

47. Toxic Epidermal Necrolysis (Diagnosis)

include the following: Sulfonamides (4.5 cases per million users per week) Chloramphenicol Macrolides (eg, erythromycin) Penicillins Quinolones (eg, ciprofloxacin, [ ] trovafloxacin [ ] ) Anticonvulsants associated with TEN include the following: Phenobarbital Phenytoin [ ] Carbamazepine Valproic acid Lamotrigine TEN in patients taking anticonvulsants has most often been reported within 2 months of starting the drug. However, some cases associated with long-term use have been reported. NSAIDs (...) Toxic Epidermal Necrolysis (Diagnosis) Toxic Epidermal Necrolysis (TEN): Background, Pathophysiology, Etiology Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMjI5Njk4LW92ZXJ2aWV3 processing > Toxic Epidermal

2014 eMedicine.com

48. Toxic Epidermal Necrolysis (Overview)

include the following: Sulfonamides (4.5 cases per million users per week) Chloramphenicol Macrolides (eg, erythromycin) Penicillins Quinolones (eg, ciprofloxacin, [ ] trovafloxacin [ ] ) Anticonvulsants associated with TEN include the following: Phenobarbital Phenytoin [ ] Carbamazepine Valproic acid Lamotrigine TEN in patients taking anticonvulsants has most often been reported within 2 months of starting the drug. However, some cases associated with long-term use have been reported. NSAIDs (...) Toxic Epidermal Necrolysis (Overview) Toxic Epidermal Necrolysis (TEN): Background, Pathophysiology, Etiology Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMjI5Njk4LW92ZXJ2aWV3 processing > Toxic Epidermal

2014 eMedicine.com

49. Toxic Epidermal Necrolysis (Diagnosis)

include the following: Sulfonamides (4.5 cases per million users per week) Chloramphenicol Macrolides (eg, erythromycin) Penicillins Quinolones (eg, ciprofloxacin, [ ] trovafloxacin [ ] ) Anticonvulsants associated with TEN include the following: Phenobarbital Phenytoin [ ] Carbamazepine Valproic acid Lamotrigine TEN in patients taking anticonvulsants has most often been reported within 2 months of starting the drug. However, some cases associated with long-term use have been reported. NSAIDs (...) Toxic Epidermal Necrolysis (Diagnosis) Toxic Epidermal Necrolysis (TEN): Background, Pathophysiology, Etiology Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMjI5Njk4LW92ZXJ2aWV3 processing > Toxic Epidermal

2014 eMedicine Emergency Medicine

50. Toxicity, Valproate (Follow-up)

Toxicity Follow-up Updated: Jan 03, 2018 Author: Asim A Abbasi, MD, FAAP; Chief Editor: Michael A Miller, MD Share Email Print Feedback Close Sections Sections Valproate Toxicity Follow-up Further Outpatient Care After the patient's condition is stabilized and he or she is discharged, an ongoing relationship between the patient and a mental health professional is recommended if the overdose was intentional. Next: Further Inpatient Care Depending on level of toxicity, patients with valproic acid (...) to a psychiatric facility. However, this disposition highly depends on the patient's symptoms and the amount of ingestion. In one multicenter case series of 134 patients with valproic acid ingestions (80 with toxic VPA levels at admission), the mean hospital stay for all patients was 44.7 hours (standard deviation, 28 h). [ ] Previous Next: Complications Valproic acid is used in the treatment of mood disorders in addition to its use as an antiseizure medication. Emergency personnel must consider

2014 eMedicine Emergency Medicine

51. Toxicity, Valproate (Diagnosis)

Updated: Jan 03, 2018 Author: Asim A Abbasi, MD, FAAP; Chief Editor: Michael A Miller, MD Share Email Print Feedback Close Sections Sections Valproate Toxicity Overview Practice Essentials Although most cases of valproate (valproic acid [VPA]) overdose are benign, serious toxicity, including death, may occur after acute ingestion. Signs and symptoms Few historical features are specifically suggestive of valproate toxicity. The following information should be elicited if possible: Exact time (...) for mood stabilization, as opposed to its initial use predominantly as an anticonvulsant. In recent years, however, VPA exposures have stabilized at a lower rate, with 3211 single exposures reported in 2010 and 3060 reported in 2016. [ , ] The international frequency of valproic acid toxicity is unknown. Age-, sex-, and race-related demographics Although most acute VPA ingestions occur in persons older than 20 years, age does not influence outcomes after an acute ingestion. Children younger than 3

2014 eMedicine Emergency Medicine

52. Toxicity, Valproate (Treatment)

=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvODE5MzE1LXRyZWF0bWVudA== processing > Valproate Toxicity Treatment & Management Updated: Jan 03, 2018 Author: Asim A Abbasi, MD, FAAP; Chief Editor: Michael A Miller, MD Share Email Print Feedback Close Sections Sections Valproate Toxicity Treatment Approach Considerations Treatment of patients with valproate (valproic acid [VPA]) toxicity is mainly supportive, commonly including the following: Management of airway, breathing, and circulation (ABCs) Oxygenation Administration of intravenous (IV) fluids Monitoring (...) , Gaillard T, Brisou P, Vest P. Acute overdose of enteric-coated valproic acid and olanzapine: unusual presentation and delayed toxicity. Clin Toxicol (Phila) . 2012 Apr. 50(4):268. . Lai MW, Klein-Schwartz W, Rodgers GC, et al. 2005 Annual Report of the American Association of Poison Control Centers' national poisoning and exposure database. Clin Toxicol (Phila) . 2006. 44(6-7):803-932. . Nanau RM, Neuman MG. Adverse drug reactions induced by valproic acid. Clin Biochem . 2013 Oct. 46(15):1323-38

2014 eMedicine Emergency Medicine

53. Toxicity, Carbamazepine (Overview)

). The autoinduction process takes about 4 weeks. Carbamazepine stimulates the synthesis of many monooxygenase and conjugating enzymes, which leads to the metabolism of many medications. [ ] In terms of drug interactions, carbamazepine induces the metabolism of other anticonvulsant drugs such as phenytoin, clonazepam, primidone, valproic acid, and ethosuximide. This may lead to subtherapeutic levels of these drugs, especially phenytoin. In addition, carbamazepine reduces the duration and action of many therapeutic (...) Toxicity, Carbamazepine (Overview) Pediatric Carbamazepine Toxicity: Background, Pathophysiology, Epidemiology Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTAxMTI0MC1vdmVydmlldw== processing > Pediatric

2014 eMedicine Pediatrics

54. Toxicity, Carbamazepine (Diagnosis)

). The autoinduction process takes about 4 weeks. Carbamazepine stimulates the synthesis of many monooxygenase and conjugating enzymes, which leads to the metabolism of many medications. [ ] In terms of drug interactions, carbamazepine induces the metabolism of other anticonvulsant drugs such as phenytoin, clonazepam, primidone, valproic acid, and ethosuximide. This may lead to subtherapeutic levels of these drugs, especially phenytoin. In addition, carbamazepine reduces the duration and action of many therapeutic (...) Toxicity, Carbamazepine (Diagnosis) Pediatric Carbamazepine Toxicity: Background, Pathophysiology, Epidemiology Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTAxMTI0MC1vdmVydmlldw== processing > Pediatric

2014 eMedicine Pediatrics

55. Toxic Epidermal Necrolysis (Overview)

include the following: Sulfonamides (4.5 cases per million users per week) Chloramphenicol Macrolides (eg, erythromycin) Penicillins Quinolones (eg, ciprofloxacin, [ ] trovafloxacin [ ] ) Anticonvulsants associated with TEN include the following: Phenobarbital Phenytoin [ ] Carbamazepine Valproic acid Lamotrigine TEN in patients taking anticonvulsants has most often been reported within 2 months of starting the drug. However, some cases associated with long-term use have been reported. NSAIDs (...) Toxic Epidermal Necrolysis (Overview) Toxic Epidermal Necrolysis (TEN): Background, Pathophysiology, Etiology Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMjI5Njk4LW92ZXJ2aWV3 processing > Toxic Epidermal

2014 eMedicine Emergency Medicine

56. Toxicity, Valproate (Overview)

Updated: Jan 03, 2018 Author: Asim A Abbasi, MD, FAAP; Chief Editor: Michael A Miller, MD Share Email Print Feedback Close Sections Sections Valproate Toxicity Overview Practice Essentials Although most cases of valproate (valproic acid [VPA]) overdose are benign, serious toxicity, including death, may occur after acute ingestion. Signs and symptoms Few historical features are specifically suggestive of valproate toxicity. The following information should be elicited if possible: Exact time (...) for mood stabilization, as opposed to its initial use predominantly as an anticonvulsant. In recent years, however, VPA exposures have stabilized at a lower rate, with 3211 single exposures reported in 2010 and 3060 reported in 2016. [ , ] The international frequency of valproic acid toxicity is unknown. Age-, sex-, and race-related demographics Although most acute VPA ingestions occur in persons older than 20 years, age does not influence outcomes after an acute ingestion. Children younger than 3

2014 eMedicine Emergency Medicine

57. Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis (PubMed)

Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis To determine whether valproic acid (VPA), a histone deacetylase inhibitor that showed antioxidative and antiapoptotic properties and reduced glutamate toxicity in preclinical studies, is safe and effective in amyotrophic lateral sclerosis (ALS) using a sequential trial design.Between April 2005 and January 2007, 163 ALS patients received VPA 1,500mg or placebo daily. Primary end point was survival. Secondary outcome

2009 EvidenceUpdates

58. Valproic acid

of valproate, leading to decreased valproate concentrations : may increase warfarin concentration and prolong bleeding time. : may increase zidovudine serum concentration and lead to toxicity. Overdose and toxicity [ ] Therapeutic range of valproic acid Form Lower limit Upper limit Unit Total (including ) 50 125 µg/mL or mg/l 350 700 μmol/L Free 6 22 µg/mL or mg/l 35 70 μmol/L Excessive amounts of valproic acid can result in sleepiness, , , , , , and death. In general, serum or plasma valproic acid (...) . Sztajnkrycer MD (2002). "Valproic acid toxicity: overview and management". J. Toxicol. Clin. Toxicol . 40 (6): 789–801. : . . Patsalos PN, Berry DJ (2013). "Therapeutic drug monitoring of antiepileptic drugs by use of saliva". Ther Drug Monit . 35 (1): 4–29. : . . Thanacoody RH (2009). "Extracorporeal elimination in acute valproic acid poisoning". Clin Toxicol . 47 (7): 609–616. : . . R. Baselt, Disposition of Toxic Drugs and Chemicals in Man , 8th edition, Biomedical Publications, Foster City, CA, 2008

Full Text available with Trip Pro

2012 Wikipedia

59. Placenta Transfer and Toxicokinetics of Valproic Acid in Pregnant Cynomolgus Monkeys (PubMed)

Placenta Transfer and Toxicokinetics of Valproic Acid in Pregnant Cynomolgus Monkeys Placenta transfer study in non-human primate (NHP) is one of the crucial components in the assessment of developmental toxicity because of the similarity between NHP and humans. To establish the method to determine placenta transfer in non-human primate, toxicokinetics of valproic acid (VPA) , a drug used to treat epilepsy in pregnant women, were determined in pregnant cynomolgus monkeys. After mating

Full Text available with Trip Pro

2010 Toxicological research

60. Valproic Acid With Chemoradiotherapy for Non-Small-Cell Lung Cancer

and oral valproic acid (VA)will be started at the first day of RT. Follow up will be conducted every 3 months after completion of the study treatment. Toxicity will be assessed using CTCAE, based on clinical examination and laboratory tests during the study treatment and at follow up visits. Response to treatment will be evaluated using RECIST criteria. Overall and progression free survival (OS and PFS) will be estimated using the Kaplan-Meier method. Condition or disease Intervention/treatment Phase (...) Lung Cancer Study Start Date : February 2011 Estimated Primary Completion Date : February 2013 Estimated Study Completion Date : February 2015 Resource links provided by the National Library of Medicine related topics: related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Valproic acid, Chemoradiotherapy Drug: Valproic acid 800mg per day for entire period of RT Other Name: Sodium valproate Outcome Measures Go to Primary Outcome Measures : Toxicity [ Time Frame: 24

2010 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>